Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros











Intervalo de ano de publicação
1.
J Child Neurol ; 15(3): 161-5, 2000 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-10757471

RESUMO

This is a prospective study designed to evaluate the efficacy and safety of vigabatrin as first-choice monotherapy in infants with West syndrome. One hundred sixteen patients with newly diagnosed West syndrome were studied in Argentina, from June 1994 to April 1998. The follow-up ranged from 17 to 40 months (mean, 23 months). Vigabatrin was administered upon diagnosis, starting with a 50-mg/kg/day dose and increasing 50 mg/kg every 48 hours to reach a maximum dose of 200 mg/kg/day. Twenty-nine percent of cases were considered to be cryptogenic or idiopathic West syndrome, while 70.7% were symptomatic. Response to vigabatrin treatment was measured according to five categories: (1) seizures free: 61.8% of cases for cryptogenic and 29.3% for symptomatic West syndrome, (2) more than 75% reduction in the number of infantile spasms: 14.7% for cryptogenic and 26.8% for symptomatic West syndrome, (3) from 50% to 74% reduction in the number of infantile spasms: 11.8% for cryptogenic and 24.4% for symptomatic West syndrome, (4) poor or null response: 11.8% for cryptogenic and 18.3% for symptomatic West syndrome, and (5) increase in the number of infantile spasms: one symptomatic case (1.2%). All seizure-free cryptogenic cases showed normal neuropsychic development. The most effective dose of vigabatrin was 150 mg/kg of body weight per day. The most frequent adverse events were somnolence in 19 cases and irritability in 15 cases, but none required treatment interruption.


Assuntos
Anticonvulsivantes/administração & dosagem , Espasmos Infantis/tratamento farmacológico , Vigabatrina/administração & dosagem , Anticonvulsivantes/efeitos adversos , Argentina , Pré-Escolar , Relação Dose-Resposta a Droga , Esquema de Medicação , Quimioterapia Combinada , Eletroencefalografia/efeitos dos fármacos , Feminino , Seguimentos , Humanos , Lactente , Masculino , Espasmos Infantis/diagnóstico , Resultado do Tratamento , Vigabatrina/efeitos adversos
2.
Mov Disord ; 9(3): 330-2, 1994 May.
Artigo em Inglês | MEDLINE | ID: mdl-8041374

RESUMO

Two brothers developed hemifacial spasm at 63 and 70 years of age. Spasms occurred on the left and right sides of the face, respectively. Computed tomography scan and magnetic resonance imaging failed to show any abnormality. In addition, a third sibling reported a history of a peripheral facial palsy, which remitted spontaneously without sequelae. This is the fourth description of familial hemifacial spasms. This family is unique in that hemifacial spasm presented on different sides in the two brothers, and involvement was limited to one generation. Age at onset was later than for other familial cases and similar to sporadic cases.


Assuntos
Músculos Faciais/inervação , Doenças do Nervo Facial/genética , Lateralidade Funcional/genética , Transtornos dos Movimentos/genética , Espasmo/genética , Idoso , Doenças do Nervo Facial/fisiopatologia , Lateralidade Funcional/fisiologia , Humanos , Masculino , Transtornos dos Movimentos/fisiopatologia , Contração Muscular/genética , Contração Muscular/fisiologia , Exame Neurológico , Linhagem , Espasmo/fisiopatologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA